Dimethyl sulfoxide (DMSO) is an organic solvent that is widely used as cryoprotectant for freezing cells and tissues. Clinically, DMSO is considered a potent anti-inflammatory, nerve blocker (analgesic), diuretic, vasodilator and muscle relaxer. In cells, DMSO is used to induce differentiation, as a free radical scavenger, and most notably, to prevent ice formation during cryopreservation.
Akron Biotech recently participated in the ARMI | BioFabUSA Spring Summit in Manchester, NH, joining several leading research institutions and companies to continue charting a path forward for the tissue engineering industry. If we think about innovation as a process of bringing old ideas together to make new things, then ARMI is uniquely suited to
Human plasma is defined as “clear, straw colored, complex liquid that is 7% protein, 91% water, and 0.9% mineral salts” and can be derived from Source or Recovered Plasma. Today, human plasma is used to produce several ancillary materials such as Human AB Serum, Human Fibronectin, Human Serum Albumin (HSA), and Human Vitronectin. These materials
Many cancer therapies that have emerged in the past decade have been developed to increase anti-tumor immunity. Specifically, these therapies promote innate and adaptive immune responses and equip the body’s own immune system to work as a weapon against tumors. Currently, most approaches have focused on enhancing T cell responses. One such approach targets inhibitory
The problems that arise when scaling up from small research batches to pilot-scale production to large-scale manufacturing aren’t always what you might expect them to be. While the concentration of the components in the formulation may not change, plenty of subtle idiosyncrasies noticed in the research phase can become huge hurdles on the commercial end
Cardiovascular disease is the leading cause of death in the world. This field has been the focus of several novel stem/progenitor cell-based therapies. These therapies have shown promising results in human clinical trials. Studies have demonstrated that cardiac progenitor cells (CPC; c-kit+/Lin−) and cardiomyocyte-derived cells (CDCs) from human neonatal cardiac tissue can reduce heart scar
The ISCT 2019 Early Stage Professional Abstract Award is given to individuals within 10 years of receiving their terminal degrees or entry into the cell and gene therapy field, who provide top-scoring abstracts. Akron is proud to present one of these three ESP awards to David Bishop, BMedSc(Hons), MBBS, FRACP FRCPA, Westmead Hospital (Australia). Bishop’s
Mycoplasma is a class of bacteria that breaks the mold of typical bacterial classification – it does not have a cell wall. This feature makes it notoriously resistant to most common antibiotics like penicillin and cephalosporins, which are more effective on Gram-positive and Gram-negative cells (which have cell walls). Beyond being more resistant to go-to
Every year, the Medicine Maker, a global publication with a focus on the people that drive the development of small and large molecule drugs as well as advanced therapies, compiles a list of pioneers and influencers advancing the knowledge frontier, driving clinical application, and fostering industry growth. The annual Medicine Maker Power List is compiled
Scientists from Boston Children’s Hospital and Massachusetts Institute of Technology (MIT) have used alpaca-derived nanobodies to create a novel approach to CAR T cell therapy that addresses the challenge of treating patients with solid tumor cancers. Currently, CAR-T cell immunotherapy has been applied to the treatment of non-solid tumors such as acute lymphoblastic leukemia (ALL).